Niagen Bioscience
NasdaqCM:NAGE Community- 1 Narratives written by author
- 1 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
AN
Consensus Narrative from 5 Analysts
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Key Takeaways Expansion into pharmaceutical-grade Niagen and increased e-commerce performance could drive revenue growth through direct-to-consumer channels and enhanced demand. Increased R&D investments and legal settlements might strengthen the balance sheet and lead to potential high-margin pharmaceutical developments.
View narrativeUS$8.82
FV
12.1% undervalued intrinsic discount18.28%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
4 days ago author updated this narrative